Get the Stockscreener App
16.11
0.37%
-0.06
After Hours:
16.11
Adaptive Biotechnologies Corp stock is traded at $16.11, with a volume of 3.35M.
It is down -0.37% in the last 24 hours and up +9.22% over the past month.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
See More
Previous Close:
$16.17
Open:
$16.17
24h Volume:
3.35M
Relative Volume:
1.50
Market Cap:
$2.46B
Revenue:
$205.22M
Net Income/Loss:
$-121.24M
P/E Ratio:
-19.79
EPS:
-0.8141
Net Cash Flow:
$-82.81M
1W Performance:
-1.89%
1M Performance:
+9.22%
6M Performance:
+36.53%
1Y Performance:
+128.51%
1-Day Range:
$15.78
$16.82
1-Week Range:
$15.31
$16.82
52-Week Range:
$5.975
$20.76
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Name
Adaptive Biotechnologies Corp
Sector
Industry
Phone
206-659-0067
Address
1165 EASTLAKE AVE E, SEATTLE, WA
Compare ADPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
16.11 | 2.47B | 205.22M | -121.24M | -82.81M | -0.8141 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-30-25 | Initiated | Guggenheim | Buy |
| Jun-18-25 | Initiated | Craig Hallum | Buy |
| Mar-21-25 | Upgrade | Goldman | Neutral → Buy |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Dec-21-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Underperform |
| Jun-03-22 | Initiated | Piper Sandler | Neutral |
| Feb-16-22 | Reiterated | BTIG Research | Buy |
| Feb-16-22 | Reiterated | BofA Securities | Buy |
| Feb-16-22 | Reiterated | Goldman | Neutral |
| Feb-16-22 | Reiterated | JP Morgan | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Mar-03-21 | Downgrade | Goldman | Buy → Neutral |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-03-20 | Initiated | Goldman | Buy |
| Jul-23-19 | Initiated | BTIG Research | Buy |
| Jul-22-19 | Initiated | BofA/Merrill | Buy |
| Jul-22-19 | Initiated | Cowen | Outperform |
| Jul-22-19 | Initiated | Goldman | Neutral |
| Jul-22-19 | Initiated | Guggenheim | Buy |
| Jul-22-19 | Initiated | William Blair | Outperform |
View All
Adaptive Biotechnologies Corp Stock (ADPT) Latest News
Adaptive Biotechnologies discloses it's raising $15 million for subsidiary - The Business Journals
Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Biotech company heads to major healthcare conference in San Francisco - Stock Titan
Adaptive Biotechnologies announces subsidiary’s Series A financing round By Investing.com - Investing.com Nigeria
Adaptive Biotechnologies CorpUnit held initial closing $15 million Series A financingSEC filing - marketscreener.com
Adaptive Biotechnologies announces subsidiary’s Series A financing round - Investing.com
Adaptive Biotechnologies Announces Series A Financing for Subsidiary - TradingView — Track All Markets
Adaptive biotechnologies CPO Lo sells $76,895 in ADPT stock - Investing.com
Adaptive biotechnologies CPO Lo sells $76,895 in ADPT stock By Investing.com - Investing.com UK
Adaptive Biotechnologies: 2026 Is The Durability Test, Not The Hype Cycle (ADPT) - Seeking Alpha
Adaptive Biotechnologies (ADPT) Leads Life Sciences Sector with 183.57% YTD Gain - GuruFocus
Adaptive Biotechnologies (ADPT): Valuation Check After New Pfizer T-Cell Discovery and AI Drug Collaboration Deals - simplywall.st
Adaptive Biotechnologies is the top performing life sciences tools and services stock YTD (ADPT:NASDAQ) - Seeking Alpha
Adaptive Biotechnologies (ADPT) Is Up 10.1% After New Pfizer TCR-AI Collaboration Milestone DealWhat's Changed - simplywall.st
Will Adaptive Biotechnologies Corporation stock see PE expansionTrade Risk Summary & Real-Time Market Trend Scan - Улправда
How Adaptive Biotechnologies Corporation (1HM) stock trades after rate cutsGlobal Markets & High Accuracy Trade Signal Alerts - Улправда
How Adaptive Biotechnologies Corporation stock responds to policy changesMarket Activity Recap & Fast Moving Stock Trade Plans - Улправда
First Week of February 2026 Options Trading For Adaptive Biotechnologies (ADPT) - Nasdaq
Why Adaptive Biotechnologies Corporation stock remains undervaluedJuly 2025 Technicals & Trade Opportunity Analysis Reports - Улправда
Adaptive Biotechnologies Insider Sold Shares Worth $1,773,267, According to a Recent SEC Filing - marketscreener.com
Adaptive Biotechnologies Exec Sells Shares Under Trading Plan - TradingView — Track All Markets
Officer Lo Sells 113,890 ($1.8M) Of Adaptive Biotechnologies Corp [ADPT] - TradingView — Track All Markets
Adaptive Biotechnologies (ADPT): Valuation Check After New Pfizer Collaborations and Surging 2024 Share Price - simplywall.st
Adaptive Biotechnologies stock rises after Pfizer deals worth up to $890M - Investing.com
Pfizer Faces Another Quiet Year As Patent Losses Cloud 2026 Outlook: Analyst - Benzinga
Adaptive Biotechnologies inks two agreements with Pfizer in immunology - Investing.com India
Adaptive signs deal with Pfizer worth up to $890 million for rheumatoid arthritis research - Reuters
Adaptive Biotechnologies stock rises after Pfizer deals worth up to $890M By Investing.com - Investing.com South Africa
Adaptive Biotechnologies signs non-exclusive deals with Pfizer worth up to $890 million - Yahoo Finance
Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer - The Manila Times
How Investors Are Reacting To Adaptive Biotechnologies (ADPT) clonoSEQ Data Shaping MRD-Guided Cancer Care - Yahoo Finance
Insider Sell: Robert Hershberg Sells 22,968 Shares of Adaptive B - GuruFocus
Adaptive Biotechnologies Director Sells Shares - TradingView — Track All Markets
Adaptive Biotechnologies (ADPT) falls 24.5% as execs dispose millions of stake - MSN
Dir Hershberg Files To Sell 22,968 Of Adaptive Biotechnologies Corp [ADPT] - TradingView — Track All Markets
Take off with Adaptive Biotechnologies Corp (ADPT): Get ready for trading - setenews.com
Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease - The Manila Times
Adaptive Biotechnologies to Discuss clonoSEQ Technology and Minimal Residual Disease at Jefferies Fireside Chat - Quiver Quantitative
Adaptive Biotechnologies (Nasdaq: ADPT) to discuss MRD, clonoSEQ at Jefferies chat - Stock Titan
Adaptive Biotechnologies chief commercial officer sells $212k in stock - Investing.com
Adaptive Biotechnologies (ADPT) Falls 24.5% as Execs Dispose Millions of Stake - Insider Monkey
Adaptive Biotechnologies CEO Chad M Robins Sells $3M in Company Shares - StocksToTrade
Adaptive Biotechnologies (ADPT) Showcases clonoSEQ Test Advances at ASH Meeting - GuruFocus
Adaptive Biotechnologies Stock Declines After Insider Sale - timothysykes.com
December Disappointments: 10 Big Names Troubled Early - Insider Monkey
Seattle InnoLayoffs at Adaptive I Rover's marketing efforts - The Business Journals
Adaptive Biotechnologies’ Stock Faces Turmoil Amid Insider Selling - StocksToTrade
Adaptive Biotechnologies Corporation Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ Data Driving Treatment Interventions at 2025 ASH Annual Meeting - marketscreener.com
Adaptive Biotechnologies Highlights Expanded Clinical Use of clonoSEQ® Test at 67th ASH Annual Meeting - Quiver Quantitative
Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting - The Manila Times
Adaptive Biotechnologies (Nasdaq: ADPT) shows clonoSEQ MRD guiding blood cancer care at ASH 2025 - Stock Titan
Adaptive Biotechnologies Corp Stock (ADPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):